frame image
frame image

Meet the players who are changing the way we think about medical innovation and open your mind to “the audacity of imagination.” We will explore how the latest advances from our labs will benefit your health as we chart the pathway from revolutionary concept to your medicine chest.

8:00 a.m. Keynote breakfast

Gil Van Bokkelen, PhD
Chairman and CEO of Athersys

Gil Van Bokkelen, PhD, has served as chief executive officer and chairman of Cleveland-based Athersys since August 2000. Dr. Van Bokkelen co-founded Athersys in October 1995. Dr. Van Bokkelen is Chairman (ex officio) of the Alliance for Regenerative Medicine, a Washington, DC-based consortium of companies, patient advocacy groups, disease foundations, and clinical and research institutions that are committed to the advancement of the field of regenerative medicine. He received his PhD in genetics from Stanford University School of Medicine, his BA in economics and BA in molecular biology from the University of California at Berkeley. He is chairman of the Board of Governors for the National Center for Regenerative Medicine, and serves on the Biotechnology Industry Organization's ECS board of directors, the McGowan Institute for Regenerative Medicine and the Regenerative Medicine Foundation.

9:30 a.m. Panel Discussions

How do you bottle the lightning?

Through relationships with leading industry experts — from venture capital to Big Pharma — we are propelling breakthroughs from the present to the future of medicine. Hear industry perspective on the potential of our recent discoveries and plans for progression from idea to real therapies for patients.

Mark Chance, PhD

Vice Dean for Research,
Case Western Reserve University School of Medicine

Mark Chance, PhD, is vice dean for research, director of the Center for Proteomics and Bioinformatics, professor in the Department of General Medical Sciences and the Charles W. and Iona A. Mathias Chair in Cancer Research at Case Western Reserve University School of Medicine. He also is chief scientific officer and co-founder of NeoProteomics Inc. He has conducted extensive protein research around diabetes mellitu s and developed novel methods of biomarker detection and validation. Dr. Chance received his bachelor’s degree in biology from Wesleyan University and his PhD degree in biophysics from the University of Pennsylvania. Dr. Chance furthered his training as a postdoctoral research associate at AT&T Bell Laboratories. He served as chair of the NIH Biomedical Technology Center Directors’ Organization from 2001-2003, and chair of the Scientific Advisory Committee of the Center for Fluorescence Spectroscopy at the University of Maryland in 2005.

Llew Keltner, MD, PhD
Chief Executive Officer, AgonOx, Inc. and
Chief Executive Officer, Epistat, Inc.

Llew Keltner, MD, PhD [MS '82, GRS '83, MED '84], is chief executive officer of AgonOx and has worked in the Biotech industry for the past 25 years, including leadership roles at Novici Biotech, Light Sciences Oncology and Metastat. Dr. Keltner also advises health care and financial companies on raising capital. His work has been published in numerous health care research and business trade publications. Dr. Keltner received his MS in Epidemiology and Biostatistics, his PhD in Biomedical Informatics and his MD from Case Western Reserve University. He is a member of the American Association of Clinical Chemistry, American Medical Association, International Association of Tumor Marker Oncology, Drug Information Association and American Society of Clinical Oncology.

Lori Taylor, PhD
VP and Commercial Franchise Lead, Immune Mediated Inflammatory Diseases, Vertex Pharmaceuticals

Lori Taylor, PhD [BS '89, GRS '84], has been with Vertex Pharmaceuticals since June 2012. She was previously with Elan Pharmaceuticals beginning in 2006, in San Francisco, holding a variety of positions, including head of the TYSABRI business, vice president of Medical Affairs and TYSABRI team leader. Prior, Dr. Taylor was at Abbott Laboratories in the Chicago area, where she led the life cycle management efforts and associated market preparation for HUMIRA, now a top-selling pharmaceutical. Dr. Taylor received a BS in biochemistry and PhD in neurosciences from Case Western Reserve University and completed postdoctoral training at Harvard University.

Larry Posner, MD
General Partner, Vedanta Capital

Lawrence E. Posner, MD [MED’74], has more than 25 years of experience in pharmaceutical research and development, including executive positions with Yamanouchi Pharma America, Inc., Bayer’s Pharmaceutical Division, and the Medical Research Division of Lederle Laboratories, among others. Dr. Posner held multiple leadership roles at Bayer’s Pharmaceutical Division, and has been involved in the development and registration of 18 new drugs during his career. He earned his MD at Case Western Reserve University and later specialized in medical oncology and tumor virology at the National Cancer Institute. In 2006, he received a Master’s in economics. Dr. Posner currently serves on the Board of Directors of Labopharm, Inc. of Laval, Quebec and on the Board of Directors of Noxxon Pharma AG Berlin, Germany. He is a general partner at Vedanta Capital in New York City.

Patrick J. Fortune, PhD
General Manager,
Cleveland Clinic Innovations

Patrick J. Fortune, PhD, serves as senior general manager, Cleveland Clinic Innovations. Prior to joining Cleveland Clinic, he was a Partner at Boston Millennia Partners, where he invested in early stage companies in pharmaceuticals and medical devices. He was previously president and chief operating officer of New Era of Networks, vice president at Monsanto, vice president at Bristol Myers Squibb, group president at Baxter International, and vice president R&D at Baxter International. He has been responsible for nurturing start-up activities from idea to prototype to standalone business. Dr. Fortune holds a BA from the University of Wisconsin, an MBA from Northwestern University, and a PhD in physical chemistry from the University of Wisconsin.

The electric ideas

Sound science coupled with bold ideas lights the way to future cures. Join in discussion with the innovators behind the brightest discoveries from the School of Medicine’s labs.

Moderator: Reid Leonard, PhD
President, Merck Research Venture Fund

Reid Leonard, PhD, is executive director, licensing and managing director of the Merck Research Ventures Fund (MRVF), a strategic investment vehicle that participates in both direct and fund-to-fund biotech investments. As Merck’s Boston-based licensing “scout”, Reid interacts regularly with biotechnology companies and academic institutions to identify and evaluate partnership opportunities that will enhance Merck’s pipeline. Prior to his career in business development, Dr. Leonard conducted basic research and drug discovery on ion channels at Merck. Reid is a graduate of Brandeis University, with a dual BA in biology and psychology. He earned a PhD in biology from Purdue University and completed postdoctoral training in molecular pharmacology at Caltech.

Susann Brady-Kalnay, PhD
Professor, Department of Molecular Biology and Microbiology

Susann M. Brady-Kalnay, PhD, is a professor of Molecular Biology and Microbiology, Neurosciences, Pathology and Division of General Medical Sciences/Oncology at Case Western Reserve University. She studies cell adhesion molecules in cancer progression, with an emphasis on studying the disregulation of the molecule PTPRM in Glioblastoma multiforme. She discovered a fluorescent probe that could be used to visualize the main tumor mass and dispersive cells in glioblastoma multiforme. Dr. Brady-Kalnay graduated from the University of Dayton. She received her PhD from the Anatomy and Cell Biology department of the University of Cincinnati. Dr. Brady-Kalnay has served two terms on the leadership committee of the National Cancer Biology Training Consortium.

Jerry Silver, PhD
Professor, Department of Neurosciences

Jerry Silver, PhD, [GRS ‘74] is professor in the Department of Neurosciences at the Case Western Reserve University School of Medicine and adjunct professor in the Department of Neurosurgery at Cleveland Clinic. He studies regeneration failure in the adult spinal cord and develops strategies to maximally overcome axonal dieback and regeneration failure after cord injury to promote functional repair. Dr. Silver received his PhD from Case Western Reserve and his BS from Cleveland State University. He did post-doctoral work at Harvard University and Harvard Medical School. He is recipient of the Herbert S. Steuer Memorial Award for Meritorious Original Research in Anatomy, the Ameritec Prize, and the Christopher Reeve-Joan Irvine Research Medal. In 2011 he become a fellow of the American Association for the Advancement of Science.

Bingcheng Wang, PhD
Professor, Department of Medicine, Case Western Reserve University School of Medicine and MetroHealth Medical Center.

Bingcheng Wang, PhD, is the John and Josephine Wootton Professor in Research at MetroHealth Medical Center and Case Western Reserve University School of Medicine. He is also an adjunct professor of Chemistry at Cleveland State University and a professor and trainer in the Molecular Medicine Program at the Lerner Research Institute, Cleveland Clinic Lerner College of Medicine. His research has established the critical roles of Eph receptors in diverse physiological and disease processes including kidney development, pathogenesis of human cataract, as well as distant metastasis of multiple types of human cancer. Dr. Wang received his BS degree in Chemistry from Nanjing University. He earned his PhD from the University of Wisconsin-Madison and completed postdoctoral work at the Sanford-Burnham Institute.

Kevin Cooper, MD
Professor and Chairman, Department of Dermatology, Case Western Reserve University School of Medicine and University Hospitals Case Medical Center

Kevin D. Cooper, MD, is professor and chair of the Department of Dermatology at Case Western Reserve University School of Medicine and University Hospitals Case Medical Center and a staff physician for the Dermatology Service at the Louis Stokes Cleveland VA Medical Center. Dr. Cooper is a co-inventor of the first biologic to be FDA-approved for psoriasis, and he is a co-founder of Fluence Therapeutics, a start-up biomedical company created to develop a novel photodynamic therapy for psoriasis and lymphoma. Dr. Cooper completed training at Oregon Health Sciences University and the University of Florida and held prior positions at the University of Michigan and the National Institutes of Health.

School of Medicine Logo

Symposium on Medical Science

Friday, October 18, 2013
8:00 a.m. – Noon

Sit-down breakfast and program begin promptly at 8:30 a.m.

The Global Center for Health Innovation
1 St. Clair Avenue NE
Cleveland, OH 44114

Complimentary valet parking at W. Mall Drive

Discovery Schedule

8:00 a.m. – Registration

8:30 a.m. – Welcome from Case Western Reserve University President Barbara R. Snyder and School of Medicine Dean Pamela B. Davis

8:40 a.m. – Sit-down breakfast with keynote speaker, Gil Van Bokkelen, PhD, chairman and CEO of Athersys

9:30 a.m. – Panel discussions and dialogue with our experts